BioInsights - Breaking new ground in the clinical application of CRISPR/Cas9

Breaking new ground in the clinical application of CRISPR/Cas9

Cell & Gene Therapy Insights 2022; 8(4), 525–531

DOI: 10.18609/cgti.2022.078

Published: 9 May
Laura Sepp-Lorenzino

David McCall, Commissioning Editor, Cell & Gene Therapy Insightsspeaks to Laura Sepp-Lorenzino, Executive Vice President and Chief Scientific Officer, Intellia Therapeutics.

Laura Sepp-Lorenzino, PhD, has served as our executive vice president, chief scientific officer since May 2019. Prior to joining Intellia, Dr Sepp-Lorenzino was vice president, head of nucleic acid therapies, research leadership and a member of the external innovation team at Vertex Pharmaceuticals, Inc. from September 2017 to May 2019. From April 2014 to September 2017, Dr Sepp-Lorenzino was vice president, entrepreneur-in-residence and head of the hepatic infectious disease strategic therapeutic area at Alnylam Pharmaceuticals, Inc. Since October 2018, she has been a member of the scientific advisory board of Thermo Fisher Scientific, and in December 2020 she joined the board of directors of Taysha Gene Therapies, a biopharmaceutical company focused on developing treatments for monogenic CNS diseases. She is also a member of the BOD for Oligonucleotide Therapeutics Society and the Alliance for Regenerative Medicine. Dr Sepp-Lorenzino earned a professional degree in biochemistry from the Universidad de Buenos Aires in Argentina and a PhD in biochemistry from New York University.